Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.61 |
| ▸ | GSK3B | P49841 | 1/20 | 0.61 |
| ▸ | CCR6 | P51684 | 1/20 | 0.61 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | TLR4 | O00206 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29010977 | 0.90 | GSK3A (0.55) | GSK3AGSK3BCCR6CRBNBRD4 | |
| Methylcyclopentane SCHEMBL29010800 | 0.87 | GSK3A (0.52) | GSK3AGSK3BCCR6CRBN | |
| SCHEMBL29010973 | 0.85 | GSK3A (0.50) | GSK3AGSK3BCCR6CRBN | |
| SCHEMBL29010798 | 0.85 | GSK3A (0.50) | GSK3AGSK3BCCR6CRBN | |
| SCHEMBL4938638 | 0.85 | GSK3A (0.50) | GSK3AGSK3BCCR6CRBN | |
| SCHEMBL316039 | 0.82 | GSK3A (0.41) | GSK3AGSK3BCCR6 | |
| SCHEMBL4635968 | 0.80 | GSK3A (0.50) | GSK3AGSK3BCCR6CRBNBRD4 | |
| Propylene Oxide SCHEMBL11351469 | 0.79 | GSK3A (0.55) | GSK3AGSK3BCCR6CRBNBRD4 | |
| Bicarbonate SCHEMBL9841170 | 0.79 | GSK3A (0.42) | GSK3AGSK3BCCR6CRBN | |
| Ethane SCHEMBL11390749 | 0.78 | GSK3A (0.85) | GSK3AGSK3BCCR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116199747-A | Lidamycin prodrug, preparation method and application thereof in preparation of antitumor drugs | 中国医学科学院医药生物技术研究所 | 2023-06-02 | — | — | CN | disclosed |